摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-1-(4-(4-(3-(1-phenethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazin-1-yl)propan-2-ol | 1534376-35-6

中文名称
——
中文别名
——
英文名称
(S)-1-(4-(4-(3-(1-phenethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazin-1-yl)propan-2-ol
英文别名
(S)-1-(4-(4-(3-(1-phenethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl) piperazin-1-yl)propan-2-ol;(2S)-1-[4-[4-[3-[1-(2-phenylethyl)pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]piperazin-1-yl]propan-2-ol
(S)-1-(4-(4-(3-(1-phenethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazin-1-yl)propan-2-ol化学式
CAS
1534376-35-6
化学式
C31H34N6O
mdl
——
分子量
506.651
InChiKey
YYDLWULAODGSMR-QHCPKHFHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    38
  • 可旋转键数:
    8
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    73.2
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    3-(1-(3-fluorobenzyl)-1H-pyrazol-4-yl)-5-(4-(piperidin-4-yl)phenyl)-1-tosyl-1Hpyrrolo[2,3-b]pyridine hydrochloride 、 (S)-1-(4-(4-(3-(1-phenethyl-1H-pyrazol-4-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazin-1-yl)propan-2-ol 、 氢氧化锂 以 Methanol tetrahydrofuran water 为溶剂, 以to yield 30 mg (31.9% yield) desired product的产率得到(S)-1-(4-(4-(3-(1-phenethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazin-1-yl)propan-2-ol
    参考文献:
    名称:
    3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors
    摘要:
    本申请涉及一种新型的3-(吡唑基)-1H-吡咯[2,3-b]吡啶衍生物,其为蛋白激酶抑制剂。本发明特别涉及化合物(I)的制备、化合物的制备和制药组合物。本发明还涉及药学上可接受的盐和组成物,包括所述新型3-(吡唑基)-1H-吡咯[2,3-b]吡啶衍生物及其在治疗各种疾病中的用途。
    公开号:
    US20150336949A1
点击查看最新优质反应信息

文献信息

  • [EN] PYRAZOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION<br/>[FR] DÉRIVÉS DE PYRAZOLE INHIBANT LA PRODUCTION DE LEUCOTRIÈNE
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2014014874A1
    公开(公告)日:2014-01-23
    The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A1, A2, L1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    本发明涉及以下式(I)的化合物或其药学上可接受的盐,其中A1、A2、L1和B如本文所定义。式(I)的化合物可用作白三烯A4水解酶(LTA4H)的抑制剂,并用于治疗与LTA4H相关的疾病。本发明还涉及包含式(I)的化合物的药物组合物,使用这些化合物治疗各种疾病和疾病的方法,以及制备这些化合物的方法。
  • [EN] 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 3-(PYRAZOLYL)-1H-PYRROLO[2,3-B]PYRIDINE EN TANT QU'INHIBITEURS DE KINASE
    申请人:AURIGENE DISCOVERY TECH LTD
    公开号:WO2014006554A1
    公开(公告)日:2014-01-09
    The present application relates to novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.
    本申请涉及一种新型的3-(吡唑基)-lH-吡咯并[2,3-b]吡啶衍生物,其化学式为(I),作为蛋白激酶抑制剂。该发明特别涉及化合物的化学式(I)、化合物的制备以及其药物组成。该发明还涉及药用可接受的盐和组合物,包括所述新型的3-(吡唑基)-lH-吡咯并[2,3-b]吡啶衍生物及其在治疗各种疾病中的应用。
  • 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors
    申请人:Aurigene Discovery Technologies Limited
    公开号:US09353107B2
    公开(公告)日:2016-05-31
    The present application relates to novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.
    本申请涉及一种新型的3-(吡唑基)-1H-吡咯[2,3-b]吡啶衍生物,其为蛋白激酶抑制剂。本发明特别涉及公式(I)化合物,其制备方法以及其制备的药物组成物。本发明进一步涉及药学上可接受的盐和组成物,包括所述新型3-(吡唑基)-1H-吡咯[2,3-b]吡啶衍生物,并将其用于治疗各种疾病。
  • 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
    申请人:Aurigene Discovery Technologies Limited
    公开号:EP2867233A1
    公开(公告)日:2015-05-06
  • PYRAZOLE DERIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION
    申请人:Boehringer Ingelheim International GmbH
    公开号:EP2885285A1
    公开(公告)日:2015-06-24
查看更多